| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/HED.23696 |
| P698 | PubMed publication ID | 24634283 |
| P50 | author | Monte Willis | Q38322683 |
| Kim L Dittus | Q114358502 | ||
| P2093 | author name string | Eric Y Chang | |
| Denis C Guttridge | |||
| Christine G Gourin | |||
| Michael J Toth | |||
| Marion E Couch | |||
| Hirak Der-Torossian | |||
| Jonathan R George | |||
| P2860 | cites work | Radiation therapy impairs endothelium-dependent vasodilation in humans | Q57998107 |
| Indications for percutaneous endoscopic gastrostomy insertion: ethical aspects | Q58668313 | ||
| Changes in nutritional status and dietary intake during and after head and neck cancer treatment | Q59658030 | ||
| Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy | Q59660612 | ||
| Increased muscle ubiquitin mRNA levels in gastric cancer patients | Q60403854 | ||
| Inflammation in cancer cachexia: To resolve or not to resolve (is that the question?) | Q61066847 | ||
| Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group | Q69573484 | ||
| Corticosteroid therapy of preterminal gastrointestinal cancer | Q70019532 | ||
| Peripheral Tissue Metabolism in Cancer-bearing Man | Q70298908 | ||
| Combined hormonal infusion simulates the metabolic response to injury | Q70492114 | ||
| Circulating markers and growth factors as prognosticators in men with advanced tongue cancer | Q70715605 | ||
| Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia | Q71380526 | ||
| Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. | Q36836194 | ||
| Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease | Q36876297 | ||
| Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia | Q36934990 | ||
| Myostatin is a procachectic growth factor during postnatal myogenesis | Q37187265 | ||
| Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). | Q37330741 | ||
| Standards, Options and Recommendations for the use of appetite stimulants in oncology (2000) | Q37365174 | ||
| Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles | Q37369821 | ||
| Defective STAT signaling by the leptin receptor in diabetic mice | Q37509613 | ||
| Powerful signals for weak muscles | Q37589032 | ||
| Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. | Q37620387 | ||
| Autophagy in skeletal muscle | Q37687551 | ||
| Male hypogonadism associated with advanced cancer: a systematic review | Q37764473 | ||
| Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies | Q37781827 | ||
| Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer | Q37833217 | ||
| Pathophysiology and treatment options for cardiac anorexia | Q37843775 | ||
| Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors | Q37958368 | ||
| Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review | Q38047351 | ||
| The potential of ghrelin in the treatment of cancer cachexia. | Q38053171 | ||
| Evidence base for multimodal therapy in cachexia | Q38056647 | ||
| The role of neuropeptide Y in the antiobesity action of the obese gene product | Q38290434 | ||
| Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis | Q38452295 | ||
| Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies | Q38497790 | ||
| Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice | Q39246898 | ||
| Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice--role of toll-like-receptor 4 expressed on host cells | Q39436293 | ||
| Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients | Q39542381 | ||
| Mechanisms for skeletal muscle insulin resistance in patients with pancreatic ductal adenocarcinoma | Q39635795 | ||
| Treatment of advanced cancer of prostate with megestrol acetate | Q39870391 | ||
| Skeletal muscle metabolism in patients with malignant tumor | Q40007176 | ||
| The use and misuse of androgens | Q40297509 | ||
| Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist | Q40513267 | ||
| Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study | Q40542596 | ||
| Both inflammatory and endocrine mediators stimulate host responses to sepsis | Q40810895 | ||
| Sex hormones modulate inflammatory mediators produced by macrophages | Q40940462 | ||
| Tumor host relations. I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases | Q41027764 | ||
| Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients | Q42469575 | ||
| Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients | Q42506631 | ||
| Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation | Q42941758 | ||
| Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. | Q43148592 | ||
| Is there a role for melatonin in the treatment of neoplastic cachexia? | Q71680931 | ||
| Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients | Q71816297 | ||
| Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial | Q71833036 | ||
| Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations | Q72612752 | ||
| Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia | Q73042288 | ||
| Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6 | Q73129407 | ||
| Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth | Q73212040 | ||
| Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis | Q73298450 | ||
| Effect of insulin-like growth factor-1 (IGF-1) on muscle and bone growth in experimental models | Q73554515 | ||
| The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma | Q73687880 | ||
| Insulin-like growth factor 1 stimulates protein synthesis and inhibits protein breakdown in muscle from burned rats | Q73765101 | ||
| Plasma concentration of total leptin and human lung-cancer-associated cachexia | Q73805288 | ||
| Tumor necrosis factor increases serum leptin levels in humans | Q73941269 | ||
| Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression | Q73977470 | ||
| Altered serum amino acid profiles in head and neck cancer | Q74555144 | ||
| Mechanism of IL-1 induced inhibition of protein synthesis in skeletal muscle | Q77374538 | ||
| Circulating interleukin 6 concentrations and insulin resistance in patients with cancer | Q77755376 | ||
| Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states | Q77897177 | ||
| Ghrelin may reduce radiation-induced mucositis and anorexia in head-neck cancer | Q79214196 | ||
| Serum levels of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), -1, -2, -3, in oral cancer | Q79369700 | ||
| Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia | Q79858501 | ||
| Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract | Q80577019 | ||
| Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer | Q80658401 | ||
| Diet energy density and energy intake in palliative care cancer patients | Q81562038 | ||
| "Pharyngocise": randomized controlled trial of preventative exercises to maintain muscle structure and swallowing function during head-and-neck chemoradiotherapy | Q82119657 | ||
| Skeletal muscle protein metabolism and resistance exercise | Q82310748 | ||
| Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients | Q83170856 | ||
| A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress | Q83348642 | ||
| Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia | Q84249325 | ||
| Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract | Q84391685 | ||
| Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy | Q84511516 | ||
| Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein‐ and energy‐dense nutritional supplement containing eicosapentaenoic acid | Q85241559 | ||
| Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients--the DAHANCA 25A study | Q85560510 | ||
| Dietary advice for illness-related malnutrition in adults | Q24242209 | ||
| Thalidomide is an inhibitor of angiogenesis | Q24563363 | ||
| Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function | Q24642759 | ||
| Decreased Jun-D and myogenin expression in muscle wasting of human cachexia | Q24654557 | ||
| Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial | Q24685678 | ||
| Nutritional support in multimodal therapy for cancer cachexia | Q28264732 | ||
| A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122) | Q28269706 | ||
| Characterization of a cancer cachectic factor | Q28276181 | ||
| Latency and duration of stimulation of human muscle protein synthesis during continuous infusion of amino acids | Q28362863 | ||
| Nuclear export of phosphorylated C/EBPbeta mediates the inhibition of albumin expression by TNF-alpha | Q28365498 | ||
| Role of leptin in the neuroendocrine response to fasting | Q29618866 | ||
| Cancer cachexia: a therapeutic approach | Q31791590 | ||
| Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress | Q33209607 | ||
| Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment | Q33272573 | ||
| Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli | Q33332170 | ||
| Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia | Q33654875 | ||
| Metabolic sequelae of cancers (excluding bone marrow transplantation). | Q33715341 | ||
| Regulation of skeletal muscle protein turnover during sepsis | Q33775266 | ||
| Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites | Q33934550 | ||
| High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. | Q33945113 | ||
| Insulin-like growth factor 1 (IGF-1), a nutritional marker in patients with eating disorders. | Q33951535 | ||
| Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites | Q33953691 | ||
| Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study | Q33956807 | ||
| Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine | Q33958795 | ||
| Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells | Q33964149 | ||
| Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. | Q33964976 | ||
| Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial | Q33968290 | ||
| Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma | Q33978279 | ||
| An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort | Q33979114 | ||
| NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle | Q33985083 | ||
| Role of NF-kappaB and cytokine in experimental cancer cachexia | Q43206632 | ||
| Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure | Q43670557 | ||
| Gonadal endocrine dysfunction in patients with lung cancer: relation to responsiveness to chemotherapy, respiratory function and performance status | Q43736097 | ||
| Gender differences in tumor-induced anorectic feeding pattern in Fischer-344 rats | Q43743006 | ||
| Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group | Q43840442 | ||
| Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. | Q43930962 | ||
| Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer | Q44029537 | ||
| Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. | Q44345808 | ||
| Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment | Q44392056 | ||
| Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress | Q44556274 | ||
| Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting | Q44719380 | ||
| Short-term bed rest impairs amino acid-induced protein anabolism in humans. | Q44886673 | ||
| The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. | Q44968760 | ||
| Indomethacin preserves muscle mass and reduces levels of E3 ligases and TNF receptor type 1 in the gastrocnemius muscle of tumor-bearing mice | Q45206741 | ||
| Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. | Q45714413 | ||
| Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice | Q45735540 | ||
| Influence of dexamethasone on appetite and body weight in lung cancer patients | Q46050358 | ||
| Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization | Q46271034 | ||
| Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats | Q46367444 | ||
| Muscle myostatin signalling is enhanced in experimental cancer cachexia. | Q46519828 | ||
| Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress | Q46870625 | ||
| Thalidomide: an effective anabolic agent in gastrointestinal cancer cachexia | Q46901212 | ||
| Tissue components of weight loss in cancer patients. A new method of study and preliminary observations | Q47230373 | ||
| Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers | Q47286830 | ||
| Critical weight loss in head and neck cancer--prevalence and risk factors at diagnosis: an explorative study | Q47302575 | ||
| Adipokines and systemic inflammation in weight-losing lung cancer patients | Q47332106 | ||
| Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. | Q47360876 | ||
| Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. | Q47370718 | ||
| The deliverability, acceptability, and perceived effect of the Macmillan approach to weight loss and eating difficulties: a phase II, cluster-randomized, exploratory trial of a psychosocial intervention for weight- and eating-related distress in peo | Q47421133 | ||
| Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide | Q48299341 | ||
| Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function | Q48489136 | ||
| A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life | Q48511683 | ||
| Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome | Q48555627 | ||
| Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia | Q48713782 | ||
| Hypogonadism in male patients with cancer. | Q51498250 | ||
| Age-related changes in sex hormones affect the sex difference in serum leptin independently of changes in body fat. | Q51564559 | ||
| The effect of altered Toll-like receptor 4 signaling on cancer cachexia. | Q51723361 | ||
| Nutritional status, insulin-like growth factor-1 and quality of life in elderly women with hip fractures. | Q51979725 | ||
| Dose-dependent effects of recombinant human interleukin-6 on the pituitary-testicular axis. | Q52172986 | ||
| Ethically justified, clinically comprehensive guidelines for percutaneous endoscopic gastrostomy tube placement. | Q52274657 | ||
| Defining cancer cachexia in head and neck squamous cell carcinoma. | Q53169425 | ||
| Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. | Q54016751 | ||
| Insulin resistance in patients with colorectal cancer. | Q54398065 | ||
| Adipokines in patients with cancer anorexia and cachexia. | Q54501031 | ||
| Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. | Q55053752 | ||
| Nutritional Deterioration in Cancer: The Role of Disease and Diet | Q56765402 | ||
| Hypercatabolism and hypermetabolism in wasting states | Q57314917 | ||
| Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia | Q57584841 | ||
| Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy | Q57713790 | ||
| Systematic review of the treatment of cancer-associated anorexia and weight loss. | Q33991503 | ||
| Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. | Q34002856 | ||
| Novel treatments for cancer cachexia | Q34005616 | ||
| Cancer cachexia: developing multimodal therapy for a multidimensional problem | Q34010747 | ||
| Cachexia: a new definition | Q34013455 | ||
| A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study | Q34082057 | ||
| Skeletal muscle loss: cachexia, sarcopenia, and inactivity | Q34099406 | ||
| Sarcopenia: current concepts | Q34113122 | ||
| Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome | Q34129429 | ||
| Nitric oxide, reactive oxygen species, and skeletal muscle contraction | Q34184955 | ||
| Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle | Q34202761 | ||
| The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism? | Q34213640 | ||
| Managing cancer-related anorexia/cachexia | Q34233269 | ||
| Cytokines and oxidative signalling in skeletal muscle | Q34285777 | ||
| Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia | Q34294263 | ||
| Animal models for nutrition in cancer | Q34329032 | ||
| Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. | Q34342382 | ||
| Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer | Q34342387 | ||
| Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer | Q34342392 | ||
| Recombinant human leptin in women with hypothalamic amenorrhea. | Q34345206 | ||
| AGA technical review on parenteral nutrition | Q34405048 | ||
| Exercise and nutrition for head and neck cancer patients: a patient oriented, clinic-supported randomized controlled trial | Q34431933 | ||
| Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. | Q34439637 | ||
| A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss | Q34502402 | ||
| The role of cytokines in regulating protein metabolism and muscle function | Q34537102 | ||
| Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. | Q34550960 | ||
| Prednisolone as an appetite stimulant in patients with cancer | Q34555553 | ||
| Oxidative stress and wasting in cancer | Q34580257 | ||
| Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. | Q34580998 | ||
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer | Q34583647 | ||
| Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review | Q34636946 | ||
| Role of ghrelin axis in colorectal cancer: a novel association | Q34777976 | ||
| Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents | Q35120883 | ||
| Clinical outcomes and contributors to weight loss in a cancer cachexia clinic | Q35193902 | ||
| Crosstalk of reactive oxygen species and NF-κB signaling | Q35347850 | ||
| How corticosteroids control inflammation: Quintiles Prize Lecture 2005 | Q35545886 | ||
| Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia | Q35583902 | ||
| Physical exercise for cancer patients with advanced disease: a randomized controlled trial | Q35599837 | ||
| The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action | Q35611154 | ||
| An overview of the endocrinology of skeletal muscle | Q35717957 | ||
| Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients | Q36081975 | ||
| Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer | Q36135320 | ||
| Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. | Q36200684 | ||
| Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies | Q36202135 | ||
| Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes | Q36229974 | ||
| A meta-analysis of exercise interventions among people treated for cancer | Q36382071 | ||
| The role of Ca2+ in muscle cell damage | Q36420086 | ||
| Physical activity and quality of life in head and neck cancer survivors | Q36421772 | ||
| Cachexia: pathophysiology and clinical relevance | Q36442937 | ||
| Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components | Q36509759 | ||
| Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients | Q36569864 | ||
| Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2alpha may signal skeletal muscle atrophy in weight-losing cancer patients | Q36614674 | ||
| Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases | Q36621118 | ||
| Cancer cachexia: it's time for more clinical trials | Q36648792 | ||
| Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids | Q36694660 | ||
| Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area | Q36695496 | ||
| Oxidative stress, chronic disease, and muscle wasting | Q36723742 | ||
| Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials | Q36740661 | ||
| Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome | Q36749044 | ||
| Signalling to translation: how signal transduction pathways control the protein synthetic machinery | Q36765810 | ||
| Signaling mechanisms involved in disuse muscle atrophy | Q36766059 | ||
| The role of androgens and estrogens on healthy aging and longevity | Q36796228 | ||
| Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia | Q36820819 | ||
| Pathophysiology of cancer cachexia: much more than host-tumour interaction? | Q36824333 | ||
| P433 | issue | 7 | |
| P921 | main subject | head and neck carcinoma | Q18554836 |
| head and neck cancer | Q1783924 | ||
| neck cancer | Q18966654 | ||
| P304 | page(s) | 1057-1072 | |
| P577 | publication date | 2015-04-07 | |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Cancer cachexia update in head and neck cancer: Pathophysiology and treatment | |
| P478 | volume | 37 |
| Q59478023 | A review of weight loss and sarcopenia in patients with head and neck cancer treated with chemoradiation |
| Q47568983 | An analysis of the types of recently published research in the field of cachexia. |
| Q90734126 | Association between pretreatment obesity, sarcopenia, and survival in patients with head and neck cancer |
| Q92530719 | Combined analysis of miRNA-181a with phase angle derived from bioelectrical impedance predicts radiotherapy-induced changes in body composition and survival of male patients with head and neck cancer |
| Q89999267 | Impact of Software Selection and ImageJ Tutorial Corrigendum on Skeletal Muscle Measures at the Third Lumbar Vertebra on Computed Tomography Scans in Clinical Populations |
| Q27026488 | Malnutrition and cachexia in patients with head and neck cancer treated with (chemo)radiotherapy |
| Q42033093 | Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia |
| Q61884090 | The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia |
Search more.